Pandemic (avian) influenza

Seminars in Respiratory and Critical Care Medicine

Volumn 28, Issue 2, 2007, Pages 159-170

  Rajagopal, Sumanth ^a   Treanor, John ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Avian influenza; H5N1 influenza A virus; Human influenza virus; Pandemic influenza

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; HEMAGGLUTININ; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; RIMANTADINE; SIALIDASE; SIALIDASE INHIBITOR; ZANAMIVIR;

ASIA; AVIAN INFLUENZA; CELL STRAIN; CHEMOPROPHYLAXIS; CHINA; CLINICAL FEATURE; CONJUNCTIVITIS; DIAGNOSTIC TEST; FLU LIKE SYNDROME; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HONG KONG; HUMAN; IMMUNODIFFUSION; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H9N2; PANDEMIC; PATHOGENESIS; PNEUMONIA; POULTRY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SYMPTOMATOLOGY; VIRUS ISOLATION; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; POULTRY; ZOONOSES;

EID: 34247623661     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-976488     Document Type: Review

References (82)

1. World Bank. Avian Flu: The Economic Costs: www. worldbank.org/avianflu
2. Nicholson KG, Webster RG, Hay AJ. Textbook of Influenza. London, UK: Blackwell Science Ltd; 1998
3. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 2002;76:105-115
4. Crosby W. America's Forgotten Pandemic: Influenza of 1918. Cambridge: Cambridge University Press; 1989
5. Collins SD, Lehmann J. Trends and epidemics of influenza and pneumonia: 1918-1951. Public Health Rep 1951;66:1487-1516
6. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 2006;12:15-22
7. Nuzum JW, Pilot I, Stangl FH, Bonar BE. 1918 pandemic influenza and pneumonia in a large civil hospital. IMJ III Med J 1976;150:612-616
8. Centers for Disease Control and Prevention. Pandemics Death Toll Since 1900: http://www.pandemicflu.gov/general/
9. Taubenberger JK, Reid AH, Krafft AE, Bijwaard KE, Fanning TG. Initial genetic characterization of the 1918 "Spanish" influenza virus. Science 1997;275:1793-1796
10. Reid AH, Taubenberger JK, Fanning TG. Evidence of an absence: the genetic origins of the 1918 pandemic influenza virus. Nat Rev Microbiol 2004;2:909-914
11. Connor RJ, Kawaoka Y, Webster RG, Paulson JC. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 1994;205:17-23
12. Ito T, Couceiro JN, Kelm S, et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol 1998;72:7367-7373
13. Neumann G, Kawaoka Y. Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis 2006;12:881-886
14. Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 2001;293:1840-1842
15. Webster RG, Geraci J, Petursson G, Skirnisson K. Conjunctivitis in human beings caused by influenza A virus of seals. N Engl J Med 1981;304:911
16. Kurtz J, Manvell RJ, Banks J. Avian influenza virus isolated from a woman with conjunctivitis. Lancet 1996;348:901-902
17. Koopmans M, Wilbrink B, Conyn M, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004;363:587-593
18. Tweed SA, Skowronski DM, David ST, et al. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis 2004;10:2196-2199
19. Puzelli S, Di Trani L, Fabiani C, et al. Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003. J Infect Dis 2005; 192:1318-1322
20. Peiris M, Yuen K, Leung C, et al. Human infection with influenza H9N2. Lancet 1999;354:916-917
21. Guan Y, Shortridge KF, Krauss S, Webster RG. Molecular characterization of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong Kong? Proc Natl Acad Sci USA 1999;96:9363-9367
22. Guan Y, Shortridge KF, Krauss S, et al. H9N2 influenza viruses possessing H5N1-like internal genomes continue to circulate in poultry in Southeastern China. J Virol 2000;74:9372-9380
23. Butt KM, Smith GJD, Chen H, et al. Human infection with an avian H9N2 influenza a virus in Hong Kong in 2003. J Clin Microbiol 2005;43:5760-5767
24. Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998;279:393-396
25. Shortridge KF, Zhou NN, Guan Y, et al. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 1998;252:331-342
26. Chen H, Smith GJ, Zhang SY, et al. Avian flu: H5N1 virus outbreak in migratory waterfowl. Nature 2005;436:191-192
27. World Health Organization. Cumulative Number Of Confirmed Human Cases Of Avian Influenza A/H5N1 Reported to WHO: http://www.who.int/csr/disease/ avian_influenza/ country/cases_table_2006_08_23/en/index.html
28. Zhu QY, Qin ED, Wang N, et al. Fatal infection with influenza A (H5N1) virus in China. N Engl J Med 2006;354:2731-2732
29. Chan PK. Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis 2002;34(Suppl 2):S58-S64
30. Bender C, Hall H, Huang J, et al. Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. Virology 1999;254:115-123
31. Matrosovich M, Zhou N, Kawaoka Y, Webster R. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J Virol 1999;73:1146-1155
32. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk H. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci USA 2004;101:4620-4624
33. Shinya K, Hatta M, Yamada S, et al. Characterization of a human H5N1 influenza A virus isolated in 2003. J Virol 2005;79:9926-9932
34. Gambaryan A, Tuzikov A, Pazynina G, Bovin N, Balish A, Klimov A. Evolution of the receptor binding phenotype of influenza A (H5) viruses. Virology 2006;344:432-438
35. World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005;11:1515-1521
36. Liu J, Xiao H, Lei F, et al. Highly pathogenic H5N1 influenza virus infection in migratory birds. Science 2005; 309:1206
37. Cheung CL, Rayner JM, Smith GJ, et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 2006;193:1626-1629
38. Epidemiology of WHO-confirmed human cases of avian influenza A(H5N1) infection. Wkly Epidemiol Rec 2006; 81:249-257
39. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374-1385
40. Keawcharoen J, Oraveerakul K, Kuiken T, et al. Avian influenza H5N1 in tigers and leopards. Emerg Infect Dis 2004;10:2189-2191
41. Mounts AW, Kwong H, Izurieta HS, et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis 1999;180:505-508
42. World Health Organization. Review of Latest Available Evidence on Risks to Human Health through Potential Transmission of Avian Influenza (H5N1) through Water and Sewage: http://www.who.int/water_sanitation_health/emerging/ h5n1background.pdf
43. Olsen SJ, Ungchusak K, Sovann L, et al. Family clustering of avian influenza A (H5N1). Emerg Infect Dis 2005;11:1799-1801
44. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005;352:333-340
45. de Jong MD, Cam BV, Qui PT, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005;352:686-691
46. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 2005;11:201-209
47. To KF, Chan PK, Chan KF, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 2001;63:242-246
48. Govorkova EA, Rehg JE, Krauss S, et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 2005;79:2191-2198
49. Cheung C, Poon L, Lau A, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002;360:1831-1837
50. Seo SH, Hoffmann E, Webster RG. The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses. Virus Res 2004;103:107-113
51. Shinya K, Hamm S, Hatta M, Ito H, Ito T, Kawaoka Y. PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Virology 2004;320:258-266
52. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992;176:119-130
53. Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999;36(Suppl 1):1-11
54. Centers for Disease Control and Prevention. Safety and Dose study of Peramavir for Influenza Treatment: http://www.clinicaltrials.gov/ct/show/ NCT00297050
55. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000;48:101-115
56. Govorkova EA, Fang H, Tan M, Webster RG. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 2004;48:4855-4863
57. Leneva IA, Goloubeva O, Fenton RJ, Tisdale M, Webster RG. Efficacy of Zanamivir against avian influenza A viruses that possess genes encoding HSN1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother 2001;45:1216-1224
58. Tran TH, Nguyen TL, Nguyen TD, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004; 350:1179-1188
59. World Health Organization. WHO Rapid Advice Guidelines on Pharmacological Management of Humans Infected with Avian Influenza A (H5N1) Virus: http://www.who.int/ csr/disease/avian_influenza/guidelines/pharmamanagement/ en/index.html
60. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/ 1203/04 influenza virus in mice. J Infect Dis 2005;192:665-672
61. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000;283:1016-1024
62. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235-1240
63. de Jong MD, Thanh TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667-2672
64. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005;437:1108
65. Moscona A. Oseltamivir resistance: disabling our influenza defenses. N Engl J Med 2005;353:2633-2636
66. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004;190:1627-1630
67. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu(R)) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005;55(Suppl 1):15-21
68. Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy 2005;26:4-29
69. Katz JM, Lim W, Bridges CB, et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 1999;180:1763-1770
70. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-1943
71. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001;19:1732-1737
72. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-1351
73. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/ Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006;367:1657-1664
74. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368:991-997
75. GSK press release. GSK Reports Significant Advance in H5N1 Pandemic Flu Vaccine Programme: http://www.gsk.com/ ControllerServlet?appId=4&pageId= 402&newsid=868
76. Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003;21:1687-1693
77. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal Influenzavirus vacant in children. N Engl J Med 1998;338:1405-1412
78. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000;136:168-175
79. National Strategy for Pandemic Influenza: http://www.whitehouse.gov/ homeland/pandemic-influenza.html
80. Yuen KY, Chan PK, Peins M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998;351:467-471
81. Peiris J, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004;363:617-619
82. Tamura D, Miura T, Kikuchi Y. Oseltamivir phosphate in infants under 1 year of age with influenza infection. Pediatr Int 2005;47:484